Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$12.74 ▼ -0.58
(-4.35%)
MKT CAP: $819.7M • VOL: 2.90M
52W L $5 52W H $18
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
DNA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $170.2M | $227.0M | $251.5M |
| YoY Revenue Growth % | -25.1% | -9.7% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$315.3M | -$559.8M | -$864.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$313.0K | -$547.0K | -$893.0K |
| EBITDA (Normalized) | -$309.1M | -$509.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$171.1M | -$319.6M | -$295.5M |
| Capital Expenditures (CapEx) | $7.7M | $62.5M | — |
| Free Cash Flow (FCF) | -$178.7M | -$382.1M | -$295.5M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $167.2M | $561.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $508.6M | $716.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DNA.